[Home]
[Reports] [Startups]
[Press Releases] [ONLINE
STORE] [site map]
[Home]
[Reports] [Startups]
[Press Releases] [ONLINE
STORE] [site map]
|
Tissue Engineering and Cell Therapy 2010 Tissue Engineering, Cell Therapy and Transplantation: Products, Technologies & Market Opportunities, Worldwide, 2009-2018 · 314 pages · 74 Exhibits · 147 Company Profiles · Report #S520 · February 2010 This report reveals in detail the status and opportunities for technologies, applications and markets in tissue engineering, cell therapy and tissue/cell transplantation. The report reviews therapeutic tissue engineering, tissue reconstruction, cell therapies, tissue/organ transplantation and related technologies under various stages of development at 148 companies. The report details the technology development, projected market introduction dates and/or current and forecast market size and competitor shares for products being developed to address major causes of death and disease spanning applications in cardiovascular, neurological, orthopaedic, urological, skin, dental, ophthalmological, gastrointestinal, organ transplant, cancer and others. The report details the status of product development and assesses the current and forecast worldwide market for tissue engineering, cell therapy and transplantation. The report provides market size and share data, with forecast market data to 2018, for the U.S., Europe, Asia/Pacific and Rest of World. The report establishes the current worldwide market size for major technology segments as a baseline for and projecting growth in the market over a ten-year forecast and assesses and projects the composition of the market as technologies gain or lose relative market performance over this period.
Table of Contents Executive Summary
Buyers of this report
include:
Cell therapy companies Tissue engineering companies Large device multinationals Venture capital firms Pharma companies Angel investors Industry analysts/consultants
Section 1: TISSUE ENGINEERING AND CELL THERAPY INDUSTRY BACKGROUND
1.1 Overview 1.2 Definitions 1.3 Growth of Key Procedures 1.4 Development Challenges
1.5 Unmet Clinical Needs 1.6 Business Models Based On Tissue Engineering and Cell Therapy 1.7 Timescales 1.8 Sector Challenges
1.9 Competition Intensity
Section 2: Clinical Disorders and Therapy Needs
2.1 Introduction
2.2 Cancer
2.3 Dental
2.4 ENT/Respiratory/Cardiopulmonary
2.5 Gastrointestinal
2.6 Gynecology 2.7 Neurological
2.8 Ophthalmology
2.9 Organ Transplantation
2.10 Orthopedic
2.11 Skin/Integumentary
2.12 Urological
Section 3: Product & Company-Sponsored Technology Developments (Approved and in Development)
3.1 Introduction 3.2 Cancer
3.3 Cardiovascular and Vascular 3.4 Dental 3.5 ENT/Respiratory/Cardiopulmonary 3.6 Gastrointestinal 3.7 Gynecology 3.8 Neurological 3.9 Ophthalmology 3.10 Organ Transplantation and Related Therapies
3.11 Orthopedic 3.12 Skin/Integumentary
3.13 Urological
Section 4: Markets, Potential Markets, and COMPETITOR SHARES
4.1 Worldwide Potential Market for Tissue Engineered Products 4.2 Cardiovascular and Vascular 4.3 Neurological 4.4 Orthopedic 4.5 Urological 4.6 Skin/Integumentary 4.7 Dental 4.8 Organ Transplantation and Preservation 4.9 Ophthalmology 4.10 General, Gastrointestinal, Gynecologic and Other 4.11 Cancer 4.12 Cord Blood and Cell Banking
Section 5: Company profiles
5.1 3DM Inc. 5.2 Aastrom Bioscience Inc. 5.3 Acorda Therapeutics Inc. 5.4 Advanced BioHealing, Inc. 5.5 Advanced Cell Technology, Inc. 5.6 Advanced Medical Solutions PLC 5.7 Aeolus Pharmaceuticals 5.8 Aldagen, Inc. 5.9 Alexion Pharmaceuticals 5.10 Angioblast Systems, Inc. 5.11 Angiotech Pharmaceuticals, Inc. 5.12 Ariad Pharmaceuticals Inc. 5.13 Arteriocyte Medical Systems, Inc. 5.14 Athersys, Inc. 5.15 Avax Technologies Inc. 5.16 Avita Medical Limited 5.17 Baxter International Inc. 5.18 BeFutur Biotechnologies 5.19 Bio Nova International 5.20 Biocomposites 5.21 Biocoral Inc. 5.22 Bioheart Inc. 5.23 BioHybrid Technologies 5.24 BioLife Solutions Inc. 5.25 Biomet, Inc. 5.26 BioMimetic Therapeutics 5.27 BioSante Pharmaceuticals, Inc. 5.28 BioSyntech 5.29 BioTissue Technologies GmbH 5.30 Boston Scientific Corporation 5.31 BrainStorm Cell Therapeutics, Inc. 5.32 Breonics Perfusion Technologies, Inc. 5.33 BTG International Ltd. 5.34 California Stem Cells Inc. 5.35 Capricor, Inc. 5.36 Capstone Therapeutics 5.37 Celgene Corporation 5.38 CellECT Bio Inc. 5.39 Cellerix SA 5.40 CellSeed, Inc. 5.41 CellTran Ltd. 5.42 Cellular Dynamics International 5.43 Centocor Ortho Biotech, Inc. 5.44 Cerco Medical 5.45 co.don AG 5.46 ConMed Linvatec 5.47 Cook Group 5.48 CorCell Companies, Inc. 5.49 Cryo-Cell International, Inc. 5.50 CryoLife, Inc. 5.51 Curis Inc. 5.52 Cyclacel Pharmaceuticals, Inc. 5.53 Cytograft Tissue Engineering 5.54 Cytomatrix LLC 5.55 Cytori Therapeutics Inc. 5.56 ES Cell International 5.57 Exactech, Inc. 5.58 Excorp Medical, Inc. 5.59 FibroGen, Inc. 5.60 Fidia Advanced Biopolymers/Anika Therapeutics, Inc. 5.61 Forticell Bioscience, Inc. 5.62 Gamida Cell Ltd. 5.63 Garnet BioTherapeutics 5.64 Genta, Inc. 5.65 GenVec, Inc. 5.66 Genzyme Corporation 5.67 Geron Corporation 5.68 Glycotex, Inc. 5.69 HepaLife Technologies, Inc. 5.70 Hospira 5.71 Humacyte, Inc. 5.72 InCytu Inc. 5.73 Inion Ltd. 5.74 Innogenetics 5.75 InnovaCell Biotechnologie GmbH 5.76 Integra LifeSciences Inc. 5.77 ISTO Technologies Inc. 5.78 Johnson & Johnson Inc.
5.79 Kensey Nash 5.80 Kerecis EHF 5.81 LifeCell Inc. 5.82 LifeStem Inc. (Calba Tech, Inc.) 5.83 Living Cell Technologies Ltd. 5.84 Lonza Group Ltd. 5.85 MaxCyte 5.86 Medtronic 5.87 Mesoblast Limited 5.88 MG Biotherapeutics, LLC 5.89 MicroIslet Inc. 5.90 Miltenyi Biotec 5.91 Musculoskeletal Transplant Foundation 5.92 Natural Implant 5.93 NellOne Therapeutics, Inc. 5.94 NeoStem, Inc. 5.95 Neuralstem, Inc. 5.96 NeuroGeneration, Inc. 5.97 NeuroNova AB 5.98 Neurotech 5.99 Novartis International AG 5.100 Novo Nordisk A/B 5.101 OncoMed Pharmaceuticals 5.102 Organogenesis Inc. 5.103 Organovo, Inc. 5.104 Orthovita 5.105 OSI Pharmaceuticals 5.106 Osiris Therapeutics Inc. 5.107 Osteotech, Inc. 5.108 Pioneer Surgical Technologies 5.109 Pluristem Therapeutics Inc. 5.110 Poly-Med, Inc. 5.111 Polyganics BV 5.112 ProChon Biotech, Ltd. 5.113 Progenitor Cell Therapy Inc. 5.114 ProNeuron Biotechnologies, Inc. 5.115 Protein Polymer Technologies Inc. 5.116 ReGen Biologics Inc. 5.117 Reinnervate Ltd. 5.118 ReNeuron Ltd. 5.119 Revivicor, Inc. 5.120 RTI Biologics, Inc. 5.121 Sanofi-Aventis 5.122 Sciperio Inc. 5.123 Serica Technologies, Inc./Allergan 5.124 Sernova Corp. 5.125 Smith & Nephew Ltd. 5.126 SpineSmith Partners, LP 5.127 Stem Cell Pharma Inc. 5.128 Stem Cell Sciences UK Ltd. 5.129 Stem Cell Therapy International, Inc./Histostem Co. Ltd. 5.130 StemCell Technologies Inc. 5.131 StemCells Inc. 5.132 Stryker Corporation 5.133 Synovis Life Technologies, Inc. 5.134 Targeted Genetics Corporation 5.135 TEI Biosciences Inc. 5.136 Tengion, Inc. 5.137 Tepha Inc. 5.138 Theracell, Inc. 5.139 ThermoGenesis Corp. 5.140 TiGenix N.V. 5.141 Transition Therapeutics Inc. 5.142 TriStem Corporation 5.143 Vesta Therapeutics 5.144 ViaCell/PerkinElmer 5.145 ViaCyte, Inc. (formerly, Novocell Inc.) 5.146 Vital Therapies, Inc. 5.147 Vitrolife AB 5.148 Zimmer, Inc.
Appendix: Company Directory
List of Exhibits
Exhibit ES-1: Worldwide Tissue Engineering & Cell Therapy Market, 2009-2018 Exhibit ES-2: Worldwide Tissue Engineering & Cell Therapy Market, by Geographic Segment, 2009-2018 Exhibit ES-3: Worldwide Tissue Engineering & Cell Therapy Market, By Segment, 2009-2018 Exhibit ES-4: Worldwide Tissue Engineering & Cell Therapy Market by Manufacturer, 2009
Exhibit 2-1: Leading Companies in Stem Cell Banking Exhibit 2-2: Potential For Cardiovascular Tissue Engineering — Incidences of Applicable Surgical Procedures, 2010 Exhibit 2-3: Prevalence of Cardiovascular Disease in Adults Age 20 and Older by Age and Sex, Percent of the Population, 2003–2006 Exhibit 2-4: Incidence of Cardiovascular Disease by Age and Sex, Per 1,000 Person Years, 1980–2003 Exhibit 2-5: Incidence of Myocardial Infarction by Age and Sex, 1987–2004 Exhibit 2-6: Prevalence of Heart Failure in the United States by Age and Sex, Percent of Population Exhibit 2-7: Incidence of New Cancer Cases Worldwide by Region, 2007 Exhibit 2-8: Female Breast Cancer Incidence and Mortality Rates by Race and Ethnicity in the U.S., 2002–2006, Rate per 100,000 Exhibit 2-9: Colorectal Cancer Incidence and Mortality Rates by Race/Ethnicity and Sex in the U.S., 2001–2005, Rate per 100,000
Exhibit 3-1: Companies with Cancer Therapies Marketed or in Development Exhibit 3-2: Key Competitors in Tissue Engineering and Cell Therapies for Cardiovascular Applications Exhibit 3-3: Key Competitors in Tissue Engineering and Cell Therapies for Dental and Oral Surgery Applications Exhibit 3-4: Key Competitors in Tissue Engineering and Cell Therapies for ENT, Respiratory and Cardiopulmonary Applications Exhibit 3-5: Key Competitors in Tissue Engineering and Cell Therapies for Gastrointestinal Applications Exhibit 3-6: Key Competitors in Tissue Engineering and Cell Therapies for Gynecology Applications Exhibit 3-7: Key Competitors in Tissue Engineering and Cell Therapies for Neurology Applications Exhibit 3-8: Key Competitors in Tissue Engineering and Cell Therapies for Ophthalmology Applications Exhibit 3-9: Key Competitors in Tissue Engineering and Cell Therapies for Organ Transplant, Organ Preservation and Related Therapies Exhibit 3-10: Key Competitors in Tissue Engineering and Cell Therapies for Orthopedic, Musculoskeletal, and Spine Applications Exhibit 3-11: Key Competitors in Tissue Engineering and Cell Therapies for Skin/Integumentary Applications Exhibit 3-11: Key Competitors in Tissue Engineering and Cell Therapies for Urological Applications
Exhibit 4-1: Worldwide Tissue Engineering & Cell Therapy Market, 2009-2018 Exhibit 4-2: Worldwide Tissue Engineering & Cell Therapy Market, by Geographic Segment, 2009-2018 Exhibit 4-3: Worldwide Tissue Engineering & Cell Therapy Market, By Segment, 2009-2018 Exhibit 4-4: Worldwide Tissue Engineering & Cell Therapy Market, Cardiology, 2009-2018 Exhibit 4-5: Worldwide Tissue Engineering & Cell Therapy Market, Cardiology, by Geographic Segment, 2009-2018 Exhibit 4-6: Worldwide Tissue Engineering & Cell Therapy Market, Cardiology, by Manufacturer, 2009 Exhibit 4-7: Worldwide Tissue Engineering & Cell Therapy Market, Neurology, 2009-2018 Exhibit 4-8: Worldwide Tissue Engineering & Cell Therapy Market, Neurology, by Geographic Segment, 2009-2018 Exhibit 4-9: Worldwide Tissue Engineering & Cell Therapy Market, Neurology, by Manufacturer, 2009 Exhibit 4-10: Worldwide Tissue Engineering & Cell Therapy Market, Orthopedic/Spine, 2009-2018 Exhibit 4-11: Worldwide Tissue Engineering & Cell Therapy Market, Orthopedic/Spine, by Geographic Segment, 2009-2018 Exhibit 4-12: Worldwide Tissue Engineering & Cell Therapy Market, Orthopedic/Spine, by Manufacturer, 2009 Exhibit 4-13: Worldwide Tissue Engineering & Cell Therapy Market, Urology, 2009-2018 Exhibit 4-14: Worldwide Tissue Engineering & Cell Therapy Market, Urology, by Geographic Segment, 2009-2018 Exhibit 4-15: Worldwide Tissue Engineering & Cell Therapy Market, Urology, by Manufacturer, 2009 Exhibit 4-16: Worldwide Tissue Engineering & Cell Therapy Market, Skin/Integumentary, 2009-2018 Exhibit 4-17: Worldwide Tissue Engineering & Cell Therapy Market, Skin/Integumentary, by Geographic Segment, 2009-2018 Exhibit 4-18: Worldwide Tissue Engineering & Cell Therapy Market, Skin/Integumentary, by Manufacturer, 2009 Exhibit 4-19: Worldwide Tissue Engineering & Cell Therapy Market, Dental/Oral, 2009-2018 Exhibit 4-20: Worldwide Tissue Engineering & Cell Therapy Market, Dental/Oral, by Geographic Segment, 2009-2018 Exhibit 4-21: Worldwide Tissue Engineering & Cell Therapy Market, Dental/Oral, by Manufacturer, 2009 Exhibit 4-22: Worldwide Tissue Engineering & Cell Therapy Market, Organ Transplant/Preservation, 2009-2018 Exhibit 4-23: Worldwide Tissue Engineering & Cell Therapy Market, Organ Transplant/Preservation, by Geographic Segment, 2009-2018 Exhibit 4-24: Worldwide Tissue Engineering & Cell Therapy Market, Organ Transplant/Preservation, by Manufacturer, 2009 Exhibit 4-25: Worldwide Tissue Engineering & Cell Therapy Market, Ophthalmology, 2009-2018 Exhibit 4-26: Worldwide Tissue Engineering & Cell Therapy Market, Ophthalmology, by Geographic Segment, 2009-2018 Exhibit 4-27: Worldwide Tissue Engineering & Cell Therapy Market, Ophthalmology, by Manufacturer, 2009 Exhibit 4-28: Worldwide Tissue Engineering & Cell Therapy Market, General, Gastroenterology, Gynecology, Others, 2009-2018 Exhibit 4-29: Worldwide Tissue Engineering & Cell Therapy Market, General, Gastroenterology, Gynecology, Others, by Geographic Segment, 2009-2018 Exhibit 4-30: Worldwide Tissue Engineering & Cell Therapy Market, General, GI, Gyn, Others, by Manufacturer, 2009 Exhibit 4-31: Worldwide Tissue Engineering & Cell Therapy Market, Cancer, 2009-2018 Exhibit 4-32: Worldwide Tissue Engineering & Cell Therapy Market, Cancer, by Geographic Segment, 2009-2018 Exhibit 4-33: Worldwide Tissue Engineering & Cell Therapy Market, Cancer, by Manufacturer, 2009 Exhibit 4-34: Worldwide Tissue Engineering & Cell Therapy Market, Cord Blood and Cell Banking, 2009-2018 Exhibit 4-35: Worldwide Tissue Engineering & Cell Therapy Market, Cord Blood and Cell Banking, by Geographic Segment, 2009-2018 Exhibit 4-36: Worldwide Tissue Engineering & Cell Therapy Market, Cord Blood and Cell Banking, by Manufacturer, 2009
Exhibit 5-1: Advanced Cell Technology, Inc. and Subsidiary Consolidated Statements of Operations for the Years Ended December 31, 2008 and 2007 Exhibit 5-2: Clinical Trials Being Conducted by Mesoblast and Angioblast Exhibit 5-3: Angioblast’s Lead Products in Development Exhibit 5-4: Baxter Sales by Business, 2008, $ Billions Exhibit 5-5: BTG International’s Revenue-Producing Products and Sales Data Exhibit 5-6: Celgene’s Leading Product Candidates Exhibit 5-7: CryoLife Revenue by Product, 2008 Exhibit 5-8: Genzyme Approved/Marketed Cell Therapy–Derived Products Exhibit 5-9: Geron’s hESC-derived Product Candidates Exhibit 5-10: Osteotech Revenues, Year End 2006–2008 (000) Exhibit 5-11: Proneuron’s Developmental Product Pipeline Exhibit 5-12: RTI Biologics’ Revenues, Years Ended Dec. 31, 2006–2008, (000) Exhibit 5-13: RTI Biologics’ Products by Distributor Exhibit 5-14: TEI Biosciences’ Products, Applications and Marketing Partners
Request a report sample by emailing request to: 
Tissue Engineering, Cell Therapy and Transplantation: Products, Technologies & Market Opportunities, Worldwide, 2009-2018. (Published February 2010)
Price: $1,950 (print or PDF; add $200 for both). Site/Global License also available. Purchase for immediate PDF download via online store.
Contact: Patrick Driscoll, patrick <at> mediligence <dot> com. Tel: (949) 859-3401. Refund Policy:MedMarket Diligence print publications may be returned within 30 calendar days of purchase and must be in re-saleable condition for a refund to be issued. No refunds will be provided for digital products such as PDFs; customers are therefore advised to carefully evaluate information (website samples, descriptions, and information otherwise provided by MedMarket Diligence) on publications prior to purchase.
Copyright © 2011 MedMarket Diligence, LLC. All rights reserved.
|
Or call advanced medical technologies blog
MedMarket Diligence Reports Coverage
|
||||||||
